Advertisement for Ovulen-21 (ethynodiol diacetate mestranol), from t
Journal of the American Medical Association, December 1, 1969, p
1820–1821
Article, "A Time for Reaping," by George J. Striker, from the Searleman
June 1961
Article, "An Enovid Shopping List," from the Searleman, December 1961
Letter, dated August 9, 1962, to United States and Canadian Searlement and Can
divisional sales managers, and regional sales managers, from W.
Searle, vice president, marketing, G. D. Searle & Co
Article, "Your Health—'Pill' Scare Stories," by L. L. Coleman, M.I from the San Francisco Examiner, June 12, 1969
from the San Francisco Examiner, June 12, 1909
Article, "Powerful Drug—What a Specialist Thinks of the Pill," by Caroly
Anspacher, from the San Francisco Chronicle, April 9, 1969
Article, "Back to the Pill," from the San Francisco Chronicle, December 20, 1060
30, 1969 Letter, dated May 14, 1969, to Dear Doctor, from John C. Allen, presiden
the Nottleship Co. with accompanying enclosure
the Nettleship Co., with accompanying enclosure Letter, dated June 25, 1969, to Dear Doctor, from William L. Searle, vi
better, dated June 25, 1909, to Dear Doctor, from william L. Searie, vi
president, general manager, G. D. Searle & CoArticle, "Special Report—Informed Consent Regarding 'The Pill' as
New Drugs," from the California Medical Association News, July 1969
Curriculum Vitae of Professor Victor Wynn, M.D., M.R.C.P., F.R.
Path., professor of human metabolism, University of London
Chart, mean oral glucose tolerance test plasma glucose values in 56 contra
women and \$4 of the test group
women and 84 of the test groupChart, serum triglyceride levels in control and test groups receivi
Ovulen.
Chart, oral glucose tolerance test mean plasma glucose, NEFA, insu-
and blood pyruvate levels in women before and during oral contracepti
administration
Chart, oral glucose tolerance test mean plasma glucose, NEFA, insulin a
blood pyruvate levels in women during oral contraceptive administrati
and 6 to 12 weeks after stopping the drug
Chart, serum triglyceride levels on oral contraceptive therapy compar
with the value in the same subjects before treatment.
Chart, case 1. E.M. oral and intravenous glucose tolerance and plass
insulin levels in a young woman when receiving and not receiving or
contraceptives
Chart, case 2. A.D. oral glucose tolerance, blood pyruvate and plasm
insulin levels in a young woman when receiving and not receiving or
contraceptive medication
Chart, case 3. E.S. oral glucose tolerance and plasma insulin levels in
young woman before receiving oral contraceptives and after 3 mont
of its administration
Chart, case 3. E.S. oral glucose tolerance and plasma insulin levels in
young woman after 1 year on oral contraceptive administration, and
months after stopping
Chart, case 4. C.H. oral glucose tolerance, blood pyruvate and plass
insulin levels during and after oral contraceptive administration
Chart, case 5. C.K. serum cholestrol and triglyceride levels during as
after the administration of oral contraceptives—Blood was sampled at
hourly intervals throughout the 24-hour period
Some recent references (mostly since 1967) to the association betwee
abnormal carbohydrate metabolism, blood insulin levels, serum lip
levels and lipid metabolism and the development of occlusive vascul
disease (atherosclerosis)
References to increased thromboembolic events in patients treat
with estrogens other than in the context of oral contraceptives
Chart, frequen y of reported nausea, by percent and cycle
Chart, percent of women reporting moderate, strong or acute symptoms
oral contraceptives (O) and no oral contraceptive (NO) groups in me
strual (M), premenstrual (PM) and intermenstrual (IM) phases
most recent menstrual cycle-selected symptoms on negative affect scale
Chart, frequency of nausea in 24 cycles (all combination preparation
center No. 2)